Home
Partners
Oncology data solutions

Oncology data solutions

Our commitment to advancing cancer care with real-world multi-modal oncology data solutions makes us a valuable partner to pharmaceutical companies.

Why NeoGenomics? The data to get things done

Understanding the vital role that data play in precision oncology, NeoGenomics has the scientific expertise and innovation to help pharma companies succeed sooner.

Diverse population data

We collect data from our comprehensive clinical test menu that provides a diverse population data set representative of the entire US population, including race, ethnicity, and rural and urban communities. We have over 2 million patient profiles from over 40,000 unique providers across 4,400 healthcare organizations.

Multi-modal insights

We tailor our data to your specific needs throughout the life cycle planning process. Our multi-modal test menu captures a wide variety of various cancer diagnoses and progression throughout the cancer care continuum.

Scientific expertise

We are one of the largest oncology reference laboratories in the US, utilizing only NeoGenomics data. Our deep diagnostic and testing expertise allows us to focus on customized data solutions.

Other benefits to leveraging NeoGenomics data:

Custom use cases defined by your specific product goals and development timeline
Agile delivery methods with collated and distributed data to fit your requirements
High impact pre-launch planning, including forecasting, prevalence studies, and diagnostic landscape and testing trend analysis
Oncology and diagnostic expertise tailored to help with product development
A true partnership in seeking the answers to cancer’s most pressing questions
Data accuracy derived from an expansive portfolio of NeoGenomics-run oncology tests spanning multiple methodologies

Our national footprint

Our products

NeoEngage: Commercialization support

NeoPixel: Digital image library

NeoAccelerate: Clinical trial optimization

NeoExplore: Sample archive

NeoEngage: Commercialization support

Unparalleled data insights to drive biomarker adoption and precision oncology across your therapies

Real-time signals, deep analytics, and multi-modal insights drive your brand’s efforts in advancing biomarker testing and awareness of targeted therapies in oncology. We partner with brand teams, from emerging biotech across the spectrum to leading top-20 pharma, to help amplify their diagnostic testing and precision medicine strategy.

NeoPixel: Digital image library

Access our library for image- and AI-powered insights

Over 2.5 million digital pathology images, including hematoxylin and eosin (H&E) and immunohistochemistry (IHC), are available for machine learning and AI model development and training. Our images, paired with rich patient and clinical history, provide your team with the metadata to help you build algorithms and study biomarkers and rare cohorts efficiently.

NeoAccelerate: Clinical trial optimization

Targeted outreach to providers with eligible patients who meet your trial criteria

We identify patients who match your trial’s inclusion/exclusion criteria from our pool of over 2 million profiles, with over 500,000 patients testing annually. Our goal is to help educate and inform providers about appropriate clinical trials that may be a potential treatment option for their eligible patients. We connect sponsors with physicians and principal investigators to build the clinical trial recruitment patient pool.

NeoExplore: Sample archive

Go deeper with data: Our specimen library offers solutions for insights into the frontier of emerging biomarkers

When data gaps or existing testing modalities do not capture the necessary biomarkers to answer your important questions, we can provide access to our robust and growing library of remnant biospecimens that consist of stained and unstained slides and genomic isolates. Fueled by the footprint of our national laboratory, this is a fully renewable and growing resource that complements our existing data and testing solutions.

Unique ability to drive biomarker testing awareness through their multi-modality test menu and strong market share with predominantly community-based practices. Highly recommend working with this team of diagnostic data professionals.

— Precision medicine director at top-20 pharma company

NeoGenomics' flexibility in delivery options has made ingesting and integrating lab data into our analytics platform seamless.

⁠— Head of omnichannel products at top-20 pharma company

Utlizing NeoGenomics' HCP-level data has single-handedly been the most impactful data we implemented in 2023, with the most impactful ROI for our field team.

⁠— Commercial leader at top-20 pharma company